- Rakovina Therapeutics Inc. (RKV) is advancing its programs for malignant tumour treatment therapies
- The Canadian company is developing medicines that target and kill cancer cells
- It has three programs undergoing trials, hoping one will be approved for cancer treatment
- The programs have been designed to solve a tumour’s developed resistance to therapy
- It is now optimizing the programs and choosing the suitable molecule to target and advance for human clinical trials
- Rakovina Therapeutics Inc. (RKV) is down 29.41 per cent and is trading at $0.12 per share as of 4:00 p.m. ET
Rakovina Therapeutics (RKV) is advancing its programs for malignant tumour treatment therapies.
The Canadian biotechnology company is developing medicines that target and kill cancer cells and advance innovative cancer treatments with the potential to improve patient outcomes across multiple tumour types.
“[regarding the programs] when we’re treating a tumour, eventually the tumour will stop responding to that treatment and become resistant,” Rakovina’s Executive Chairman, Jeffrey Bacha, said.
It has three different programs to fight off dangerous tumours, its kt 2000 Next Generation PARP-inhibitors, kt-3000 Dual Action DDR-inhibitors, and its kt-4000 DNA Damaging DDR-inhibitors. It is hoping at least one of these will make it to market to treat cancer.
According to Rakovina, the programs have been designed to solve a tumour’s developed resistance to therapy and allow it to begin reacting to treatment again. All the programs are still in pre-clinical trials.
“But we have a program… by impacting into a secondary pathway that seems to overcome the resistance of treatment,” Bacha said.
The company stated it has proof-of-concept for this theory and is now moving on to optimizing the programs and choosing a suitable molecule to target and advance for human clinical trials.
Rakovina Therapeutics Inc. (RKV) is down 29.41 per cent and is trading at $0.12 per share as of 4:00 p.m. ET.
